This phenomenon might be further exploited in cancer therapy, for instance by using specific inhibitors of ribosome biogenesis, as recently been shown in ATRX-mutated ALT-positive cancers (Udugama et al. 2018). The gene discussed is ATRX; the disease is cancer.